Galapagos NV (GLPG) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Wait for pullback to $27.40. Weak momentum — blocks BUY_NOW at $28.07. Engine's entry $27.40 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Earnings in 6 days (event risk).
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus;... Read more
Wait for pullback to $27.40. Weak momentum — blocks BUY_NOW at $28.07. Engine's entry $27.40 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Earnings in 6 days (event risk). Chart setup: Death cross but MACD improving, RSI 45. Fundamentals strong but target reached (-14.1% upside). Wait for pullback. Score 6.5/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·2 ceiling hits
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $27.40. Weak momentum — blocks BUY_NOW at $28.07. Engine's entry $27.40 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Earnings in 6 days (event risk). Chart setup: Death cross but MACD improving, RSI 45. Fundamentals strong but target reached (-14.1% upside). Wait for pullback. Target $29.17 (+3.9%), stop $26.39 (−6.4%), Setup A.R:R 1.9:1. Score 6.5/10, moderate confidence.
Take-profit target: $29.17 (+6.0% upside). Target $29.17 (+3.9%), stop $26.39 (−6.4%), Setup A.R:R 1.9:1. Stop-loss: $26.39.
Analyst target reached - limited upside remaining; Earnings in 6 days (event risk); Negative momentum.
Galapagos NV trades at a P/E of 4.9 (forward -17.4). TrendMatrix value score: 9.6/10. Verdict: Buy (Wait for Entry).
18 analysts cover GLPG with a consensus score of 2.6/5. Average price target: $28.
What does Galapagos NV do?Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United...
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.